13 institutions hold shares in Phio Pharmaceuticals Corp. (PHIO), with 198.85k shares held by insiders accounting for 3.44% while institutional investors hold 6.15% of the company’s shares. The shares outstanding are 5.78M, and float is at 5.41M with Short Float at 23.90%. Institutions hold 5.94% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Gsa Capital Partners Llp with over 0.1 million shares valued at $0.27 million. The investor’s holdings represent 0.99% of the PHIO Shares outstanding. As of Sep 29, 2020, the second largest holder is Virtu Financial LLC with 35929.0 shares valued at $76888.0 to account for 0.35% of the shares outstanding. The other top investors are Citadel Advisors LLC which holds 12178.0 shares representing 0.12% and valued at over $26060.0, while Hsbc Holdings Plc holds 0.11% of the shares totaling 11337.0 with a market value of $24261.0.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is 44.61% higher on its value in year-to-date trading and has touched a low of $1.60 and a high of $6.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PHIO stock was last observed hovering at around $4.05 in the last trading session, with the day’s loss setting it -0.16% off its average median price target of $4.00 for the next 12 months. It is also 2.75% off the consensus price target high of $4.00 offered by 1 analysts, but current levels are 2.75% higher than the price target low of $4.00 for the same period.
Currently trading at $3.89, the stock is 16.80% and 30.03% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.13 million and changing -3.95% at the moment leaves the stock 55.51% off its SMA200. PHIO registered 16.82% gain for a year compared to 6-month gain of 54.98%. The firm has a 50-day simple moving average (SMA 50) of $3.2036 and a 200-day simple moving average (SMA200) of $2.5444.
The stock witnessed a 26.30% loss in the last 1 month and extending the period to 3 months gives it a 72.89%, and is 7.76% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.17% over the week and 12.47% over the month.
Phio Pharmaceuticals Corp. (PHIO) has around 11 employees, a market worth around $32.48M and $0.00M in sales. Fwd P/E is 1.50. Distance from 52-week low is 143.13% and -39.97% from its 52-week high.
Phio Pharmaceuticals Corp. (PHIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Phio Pharmaceuticals Corp. (PHIO) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Phio Pharmaceuticals Corp. is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at -$0.42.The EPS is expected to grow by 66.40% this year.
Phio Pharmaceuticals Corp. (PHIO) Insider Activity
A total of 0 insider transactions have happened at Phio Pharmaceuticals Corp. (PHIO) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Dispersyn Gerrit, the company’s President & CEO. SEC filings show that Dispersyn Gerrit bought 2,000 shares of the company’s common stock on Aug 19 at a price of $2.50 per share for a total of $5000.0. Following the purchase, the insider now owns 16377.0 shares.